Health-care stocks that were popular in ESG funds tended to score better on ESG issues than other stocks in the sector in conventional funds, according to a study.

Becton Dickinson's (BDX) second-quarter results reflect solid performance by the core Life Sciences and Interventional segments.

Becton, Dickinson's (BDX) fiscal second-quarter results likely to reflect robust performance at BD Life Sciences. However, forex is likely to have remained a woe.

Despite legal troubles with investors, Becton Dickinson has shown remarkable agility for its size with its COVID-19 testing program.

Former US vice president's firm releases 1st-quarter portfolio Continue reading...

Becton Dickinson & Co. disclosed Wednesday it was offering the sale of $1.5 billion in 10-year and 30-year notes, as the medical technology company looks to repay $1 billion in debt due this year. The offerings include $750 million in 2.823% notes due 2030 and $750 million in 3.794% notes due 2050. That compares with the yield on the 10-year Treasury note of 0.678% and the yield on the 30-year Treasury bond of 1.381%. The company said it expects to use the proceeds plus cash on hand to repay the $1 billion in 2.404% notes due 2020, and to fund a partial redemption of its 3.250% notes, also due this year. Becton Dickinson's stock, which was still inactive in premarket trading, has gained 3.0% over the past three months while the S&P 500 has lost 14.9%.

BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it has priced its previously announced registered offerings of $1.5 billion of common stock, par value $1.00 per share, at a public offering price of $240.00 per share, and $1.5 billion of depositary shares, each representing a 1/20th interest in a share of 6.00% Mandatory Convertible Preferred Stock, Series B, par value $1.00 per share, at a public offering price of $50.00 per share. Pursuant to the offerings, BD has granted the underwriters an option to purchase from BD up to an additional $225 million of common stock and up to an additional $225 million of depositary shares, in each case at the public offering price per share.

Medical Product companies have partially mitigated the impact of the pandemic with the massive adoption of COVID-19 related healthcare-support products and services.

BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it has commenced registered offerings of $1.5 billion of common stock, par value $1.00 per share, and $1.5 billion of depositary shares, each representing a 1/20th interest in its mandatory convertible preferred stock, par value $1.00 per share, Series B. Pursuant to the offerings, BD intends to grant the underwriters an option to purchase from BD up to an additional $225 million of common stock and up to an additional $225 million of depositary shares.

BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020, at 11:00 a.m. ET.

The number of global cases of COVID-19 rose above 4.31 million on Wednesday, as Russia counted another 10,000 infections and Brazil and Mexico suffered their deadliest day since the start of the pandemic.

The firm’s picks for the quarter were in medtech, defense and oil Continue reading...

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]

Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]

Madison Investments, an independently-owned investment firm, recently published its first-quarter Madison Investors Fund commentary – a copy of which can be downloaded here. During the first quarter of 2020, the Madison Investors Fund returned -20.53%, while the benchmark S&P 500 was down 19.6%. In the said letter, Madison Investments highlighted a few stocks and Becton […]

Family-influenced, niche leadership, predictable sales and promising growth prospects Continue reading...

Becton Dickinson (BDX) delivered earnings and revenue surprises of 11.84% and 3.43%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Medical technology company Becton Dickinson and Co said on Thursday it was preparing to ramp up manufacturing operations to handle demand for COVID-19 testing kits in the event of a second wave of infections in the fall. The respiratory illness caused by the novel coronavirus has infected over 1.1 million people and claimed over 70,000 lives in the United States, and experts have warned a second wave of the outbreak could be much worse as it would likely arrive with the start of the influenza season. Among the many tests Becton Dickinson has launched over the past month is a test kit that can give results in two to three hours as well as an antibody test that can confirm current or past exposure to COVID-19 in as little as 15 minutes.

BDX earnings call for the period ending March 31, 2020.

The U.S. Treasury is gearing up to auction a $3 trillion in debt to finance the growing federal budget deficit. Charles Schwab Chief Fixed Income Strategist Kathy Jones joins Yahoo Finance’s Seana Smith to discuss.